^
Association details:
Biomarker:No biomarker
Cancer:Renal Cell Carcinoma
Drug:Inlyta (axitinib) (VEGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
03/09/2012
Excerpt:
Inlyta is indicated for the treatment of adult patients with advanced renal-cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
01/27/2012
Excerpt:
INLYTA is a kinase inhibitor indicated:...as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
...the NCCN panel has included axitinib as a first-line treatment option (category 2B) for use under certain circumstances for patients of all risk groups.